Amycretin: 20mg
Weight managementDescription
Amycretin is a first-in-class unimolecular agonist of the glp-1 receptor and amylin receptors, developed by novo nordisk in once-weekly subcutaneous and once-daily oral formulations. by combining incretin and amylin biology in a single molecule, it targets complementary satiety and energy-intake pathways studied in overweight and obesity. in a phase 1b/2a subcutaneous trial, once-weekly amycretin produced dose-dependent body-weight reductions versus placebo across maintenance doses from 1.25 mg to 60 mg, with the highest escalation cohort reaching roughly −24% mean change at 36 weeks under adherence-focused estimands; gastrointestinal adverse events were frequent but aligned with early-phase incretin/amylin experience. oral amycretin phase 1 data also showed greater short-term weight loss than placebo. sponsor disclosures describe advancement toward phase 3 obesity work and positive phase 2 signals in type 2 diabetes. amycretin is not fda-approved. for research and educational purposes only. not fda-approved. consult a qualified healthcare professional.
Regulatory Notice (October 2026): Amycretin is an investigational unimolecular GLP-1/amylin receptor agonist (Novo Nordisk). It is not FDA-approved. Peer-reviewed early-phase subcutaneous and oral data exist; Phase 3 programs for obesity and type 2 diabetes have been announced by the sponsor. Research-use products are not approved medicines. Sources: Lancet 2025 amycretin SC Phase 1b/2a (doi:10.1016/S0140-6736(25)01185-7); ClinicalTrials.gov NCT05369390; Novo Nordisk public disclosures 2025–2026.
Specifications
| Amount in Vial | 20mg |
|---|---|
| BAC Water | 2ml |
| Amount per Unit | 0.1mg per unit (at 2.0ml reconstitution) |
| Recommended Dose | 1.25mg to 20mg+ once weekly (trial maintenance bands; higher doses in escalation arms) |
| Frequency | 1x per week |
| Injection Type | Subcutaneous |
| Timing | Once-weekly SC in published early-phase protocols after escalation. Oral once-daily arms studied separately. Investigational only. |
Dose Calculator
Based on 0.1mg per unit (at 2.0ml reconstitution) (100-unit insulin syringe)
Quick Reference
Reconstitution
Vial size: 20mg
Add BAC water: 2ml
Concentration: 0.1mg per unit (at 2.0ml reconstitution)
For research and educational use only.
This page provides research dosing information only. Not intended as medical advice. Consult a qualified professional before any use.